Breaking News Instant updates and real-time market news.

BAC

Bank of America

$23.43

-0.11 (-0.47%)

, C

Citi

$63.89

-0.21 (-0.33%)

11:32
06/17/17
06/17
11:32
06/17/17
11:32

Week in review: How Trump's policies moved stocks

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap compiled by The Fly: 1. BANKS: On Monday night, the Treasury Department released the first in a series of reports ordered by President Trump under a February executive order examining financial regulations. Commenting on the report, Treasury Secretary Steven Mnuchin said that "properly structuring regulation of the U.S. financial system is critical." The report, which was generally praised by banks, flagged the "sweeping scope of and excess costs" imposed by Dodd-Frank requirements and concluded that "a sensible rebalancing of regulatory principles is warranted." Publicly traded big U.S. banks include JPMorgan (JPM), Wells Fargo (WFC), Bank of America (BAC), Citi (C), Morgan Stanley (MS) and Goldman Sachs (GS). 2. DRUGS: On Thursday, Politico broke news that the White House is working on an executive order aimed at the high cost of pharmaceuticals, which President Trump criticized during his campaign and since his election. Trump has directed HHS Secretary Tom Price to come up with solutions, but the report said the president is frustrated by the slow pace of that work and wants to take an interim step before more extensive actions are taken. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), and Sanofi (SNY). 3. FOR-PROFIT EDUCATION: On Wednesday, U.S. Secretary of Education Betsy DeVos announced the Department's intention to establish rulemaking committees on Borrower Defense to Repayment and Gainful Employment regulations that were put in place by the Obama administration. Publicly traded companies in the for-profit education space include American Public Education (APEI), Bridgepoint Education (BPI), Career Education (CECO), Adtalem Global Education (ATGE), Grand Canyon (LOPE), ITT Educational (ESI), and Strayer (STRA). 4. STEEL: Legislation to address the dumping of foreign steel and aluminum in the United States will come "soon," President Trump told reporters ahead of a scheduled meeting with his Cabinet on Monday, though he gave no other details about the forthcoming proposal. Steelmakers include Nucor (NUE), U.S. Steel (X) and Steel Dynamics (STLD) while publicly traded aluminum producers include Arconic (ARNC) and Century Aluminum (CENX). 5. FEDEX: FedEx (FDX) has been meeting with President Trump regarding a potential role in his push for public-private infrastructure partnerships, CNBC's Jim Cramer reported earlier in the week, citing a source. "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.

BAC

Bank of America

$23.43

-0.11 (-0.47%)

C

Citi

$63.89

-0.21 (-0.33%)

WFC

Wells Fargo

$53.89

-0.01 (-0.02%)

JPM

JPMorgan

$86.18

-0.39 (-0.45%)

MS

Morgan Stanley

$44.48

-0.21 (-0.47%)

GS

Goldman Sachs

$221.81

-1.42 (-0.64%)

ARNC

Arconic

$26.43

-0.27 (-1.01%)

CENX

Century Aluminum

$14.35

-0.79 (-5.22%)

MRK

Merck

$62.97

-0.22 (-0.35%)

SNY

Sanofi

$47.73

-0.04 (-0.08%)

JNJ

Johnson & Johnson

$134.35

1.31 (0.98%)

BMY

Bristol-Myers

$54.46

0.18 (0.33%)

PFE

Pfizer

$32.97

0.16 (0.49%)

NVS

Novartis

$80.83

0.38 (0.47%)

AZN

AstraZeneca

$34.54

0.43 (1.26%)

GSK

GlaxoSmithKline

$43.82

0.39 (0.90%)

LLY

Eli Lilly

$81.88

-0.17 (-0.21%)

FDX

FedEx

$210.50

0.05 (0.02%)

APEI

American Public Education

$23.90

0.35 (1.49%)

BPI

Bridgepoint Education

$14.12

0.06 (0.43%)

CECO

Career Education

ATGE

Adtalem Global Education

$37.10

-0.2 (-0.54%)

LOPE

Grand Canyon

$81.33

0.74 (0.92%)

ESI

ITT Educational

STRA

Strayer

$93.17

0.08 (0.09%)

  • 19

    Jun

  • 22

    Jun

  • 26

    Jun

  • 07

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 25

    Jul

  • 27

    Jul

  • 02

    Aug

  • 08

    Aug

  • 27

    Aug

  • 22

    Sep

  • 24

    Sep

  • 12

    Oct

  • 13

    Oct

  • 17

    Oct

  • 15

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

BAC Bank of America
$23.43

-0.11 (-0.47%)

04/24/17
BREN
04/24/17
DOWNGRADE
Target $22
BREN
Hold
Bank of America downgraded to Hold from Buy at Berenberg
Berenberg analyst James Chappell downgraded Bank of America to Hold saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15.
04/19/17
RBCM
04/19/17
NO CHANGE
RBCM
Bank of America reported 'knockout' results, says RBC Capital
RBC Capital analyst Gerard Cassidy says that Bank of America reported "knockout" Q1 results that were better than the other three "Big Four" banks. The analyst says that the company has momentum heading into the rest of the year. He keeps a $26 price target and an Outperform rating on the shares.
06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
04/24/17
04/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Loop Capital with analyst David Miller citing valuation following the stock hitting a 52-week high on Friday. The strength in the stock over the last nine months has appropriately priced in the company's growth rate, said Miller, who maintains a $118 price target on Disney shares. 2. Groupon (GRPN) downgraded to Underweight on lackluster ad spend at Morgan Stanley with analyst Brian Nowak saying its recent local advertiser survey indicate lackluster forward advertiser spending and believes Groupon will need to spend more in order to grow North America Local Billings, which the Street seems to be underestimating. 3. Grainger (GWW) downgraded to Market Perform from Outperform at William Blair with analyst Ryan Merkel citing a lack of confidence in the company's repricing strategy. 4. Bank of America (BAC) downgraded to Hold from Buy at Berenberg with analyst James Chappell saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15. 5. DuPont Fabros (DFT) downgraded to Hold from Buy at Stifel with analyst Matthew Heinz saying shares are fully valued and demand patterns have shifted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
C Citi
$63.89

-0.21 (-0.33%)

06/09/17
06/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Zynga (ZNGA) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Brian Nowak saying the company's in-game innovation, starting with Poker, is resulting in higher engagement and monetization. 2. Citi (C) upgraded to Neutral from Sell at UBS with analyst Saul Martinez saying he sees an improved risk/reward at current share levels. Global growth "looks resilient," protectionist policies have not emerged, and the path forward for structural reforms in the U.S. "is not as clear." 3. Comerica (CMA) upgraded to Outperform from Market Perform at FBR Capital. 4. Camping World (CWH) upgraded to Buy from Neutral at Goldman Sachs with analyst David Tamberrino saying he expects growth to continue despite late-cycle concerns. 5. Humana (HUM) upgraded to Buy from Hold at Argus with analyst David Toung saying he is upbeat about its growth outlook following the termination of its merger deal with Aetna (AET). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/09/17
UBSW
06/09/17
UPGRADE
Target $64
UBSW
Neutral
Citi upgraded to Neutral from Sell at UBS
Citi analyst Saul Martinez upgraded Citi to Neutral and raised his price target for the shares to $64 from $58. The analyst sees an improved risk/reward at current share levels. Global growth "looks resilient," protectionist policies have not emerged, and the path forward for structural reforms in the U.S. "is not as clear," Martinez tells investors in a research note. He views Citi as an attractive capital return story.
04/13/17
NOMU
04/13/17
NO CHANGE
NOMU
'Many think Wells Fargo EPS came in below expectations, says Nomura Instinet
Nomura Instinet analyst Bill Carcache says that "many investors" believe that Wells Fargo's Q1 EPS came in below expectations, given the 3c per share in reserve releases and the 7c per share profit it realized on "market-sensitive revenues" it reported. The analyst says that the "Results were characterized by softer- than-expected top-line growth, higher expenses, and lower provision." He notes that Wells Fargo, like JPMorgan (JPM) and Citi (C), reported slower loan growth. However, he keeps a Buy rating on Wells Fargo.
WFC Wells Fargo
$53.89

-0.01 (-0.02%)

05/25/17
BERN
05/25/17
NO CHANGE
BERN
Wells Fargo valuation can increase over time, says Bernstein
Bernstein analyst John McDonald says that Wells Fargo's "underlying business remains attractive," citing its "industry leading deposit base,diverse portfolio of fee businesses, large branch network" that could be optimized, and its $300B at the Fed that could be deployed as interest rates increase. The analyst says that the company is looking to cut $4B in costs and should benefit from higher rates. He thinks that its valuation can "rise over time."
04/25/17
04/25/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Best Buy (BBY) upgraded to Buy from Neutral at BofA/Merrill with analyst Denise Chai citing stronger than expected product cycles in TVs, phones, and time smart home technology, strong online growth, increased focus on high margin services like subscription warranties and in-home services, and new cost savings opportunities. 2. JPMorgan (JPM) and American Express (AXP) were upgraded to Buy from Neutral at Guggenheim while Wells Fargo (WFC) was upgraded to Neutral from Sell. 3. Crane (CR) upgraded to Outperform from Market Perform at William Blair with analyst Nicholas Heymann citing the company's first quarter results. 4. NCI Building (NCS) upgraded to Outperform from Sector Perform at RBC Capital with analyst Robert Wetenhall saying he is more confident in the outlook of the company's end markets and the growth potential of its insulated metal panels business. The analyst believes that worries about the impact of steel price fluctuations on the company's margins are overdone, as he says that hedging can reduce the impact of such fluctuations. 5. Terex (TEX) upgraded to Overweight from Neutral at JPMorgan with analyst Ann Duignan saying the stock looks undervalued based on the company's 2020 targets. Following Terex's Q1 upside and raised 2017 outlook, the analyst upped her price target for the shares to $47 from $30. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/12/17
BARD
05/12/17
NO CHANGE
Target $58
BARD
Outperform
Wells Fargo slowly turning the corner, says Baird
Baird analyst David George noted Wells Fargo updated its 2017 guidance at its analyst day and reset expectations. He believes the estimates are conservative and continues to like the longer-term risk/reward for Wells Fargo shares. Coupled with its discounted valuation, the downside should be limited, added George, who reiterated his Outperform rating and $58 price target on Wells Fargo.
JPM JPMorgan
$86.18

-0.39 (-0.45%)

04/25/17
GUGG
04/25/17
UPGRADE
GUGG
Buy
JPMorgan upgraded to Buy from Neutral at Guggenheim
04/25/17
GUGG
04/25/17
UPGRADE
Target $96
GUGG
Buy
JPMorgan upgraded to Buy on earnings momentum at Guggenheim
As previously reported, Guggenheim upgraded JPMorgan to Buy from Neutral with a $96 price target. Analyst Eric Wasserstrom said fundamental trends have been stronger than forecasts and believes there is upside potential in the core loan forecast of 6% in 2017, indicating sustained earnings momentum even in a period without improving macro conditions.
MS Morgan Stanley
$44.48

-0.21 (-0.47%)

04/06/17
EVER
04/06/17
NO CHANGE
EVER
Glass-Steagall return wouldn't find support in Congress, says Evercore ISI
After media reports claimed White House economic adviser Gary Cohn supports rules to make banks split their consumer lending units from their investment divisions, which hints at a return of the "Glass-Steagall" law that was ended by President Clinton and a Republican Congress in 1999, Evercore ISI analyst Terry Haines said there is little support in Congress for a return of the law. Any new bank regulations can't "be done with the stroke of a pen" and will have to go through the usual regulatory process, added Haines. Publicly traded large banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
04/04/17
04/04/17
NO CHANGE

Mrogan Stanley recommends buying large banks on weakness after Q1 results
Morgan Stanley analyst Betsy Graseck expects most large banks she covers to report weaker than expected Q1 results. However, the analyst recommends that investors buy the large-cap bank stocks on weakness, as she expects them to benefit from "stronger capital return, easing regulation, lower taxes and higher rates in 2H17," along with an improved GDP outlook and strong expense management. Graseck identifies Citi (C) as her top pick heading into the quarter, as she expects its Q1 results to beat expectations, driven by strength in emerging markets and "repositioning investments" that have started to beat fruit. She expects the bank to get a boost from CCAR in June and says that it is "the biggest beneficiary of easing regulation." Other publicly traded companies in the space include Bank of America (BAC), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
06/02/17
NOMU
06/02/17
NO CHANGE
NOMU
Goldman Sachs, Morgan Stanley Q2 EPS estimates lowered at Nomura Instinet
Nomura Instinet analyst Steven Chubak cut his Q2 EPS estimate for Goldman Sachs (GS) to $3.50 from $4.04 and lowered his Q2 EPS estimate for Morgan Stanley (MS) to 77c from 86c. The consensus EPS estimates for Goldman and Morgan Stanley are $3.92 and 84c, respectively. Chubak says that Goldman has been hurt by "weaker trading and more pronounced (investment banking) declines," while Morgan Stanley is experiencing "softer" investment banking results and "more pronounced quarter-over-quarter" fixed income declines. He keeps a Neutral rating on Goldman and a Buy rating on Morgan stanley.
GS Goldman Sachs
$221.81

-1.42 (-0.64%)

04/20/17
04/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Starbucks (SBUX) upgraded to Buy from Hold at Stifel with analyst Mark Astrachan saying he views valuation as attractive and expects multiple expansion from accelerating U.S. comparable store sales growth to at least 5%-6% for the next four quarters starting in the June quarter. The analyst said shares have underperformed consumer and restaurant peers over the past 12 months and expects outperformance to be driven by meeting comp expectations. 2. Goldman Sachs (GS) upgraded to Overweight from Neutral at Atlantic Equities with analyst Christopher Wheeler telling investors investors shares are "oversold." The analyst expects the FICC business to bounce back and made just a small reduction in estimates to account for further cost measures. 3. Lear (LEA) upgraded to Outperform from Neutral at Baird with analyst David Leiker citing its recent underperformance despite improving fundamentals and a strong global auto backdrop. Leiker raised his price target to $161 from $160 on Lear shares. 4. Discovery (DISCA) upgraded to Neutral from Sell at Citi with analyst Jason Bazinet saying he sees little chance of material downward revisions to consensus earnings estimates. The analyst views the risk/reward as more balanced at current levels and upped his price target for the shares to $30 from $27. 5. Gap (GPS) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss citing the underperformance of the shares over the past 18 months and his fieldwork which suggests stability at Old Navy. The analyst raised his price target for the shares to $24 from $21. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/20/17
ATLE
04/20/17
UPGRADE
Target $252
ATLE
Overweight
Goldman Sachs upgraded to Overweight, shares 'oversold,' says Atlantic Equities
Atlantic Equities analyst Christopher Wheeler upgraded Goldman Sachs to Overweight from Neutral and lowered his price target to $252 from $254 telling investors investors shares are "oversold." The analyst expects the FICC business to bounce back and made just a small reduction in estimates to account for further cost measures.
ARNC Arconic
$26.43

-0.27 (-1.01%)

06/13/17
MSCO
06/13/17
INITIATION
Target $28
MSCO
Equal Weight
Arconic resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani resumed coverage on Arconic with an Equal Weight and a $28 price target.
06/13/17
06/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Clovis (CLVS) initiated with an Outperform at Leerink. 2. Arconic (ARNC) resumed with an Equal Weight at Morgan Stanley. 3. Tesoro (TSO) reinstated with a Conviction Buy at Goldman Sachs. 4. Golden Ocean (GOGL) initiated with a Buy at Seaport Global. 5. International Seaways (INSW) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/17
04/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arconic (ARNC) initiated with a Neutral at JPMorgan. 2. Priceline (PCLN) coverage transferred with an Outperform at Macquarie. 3. Interpublic Group (IPG) was initiated with an Outperform at Evercore ISI while Omnicom (OMC) was initiated with an In Line. 4. Alteryx (AYX) was initiated with an Outperform at William Blair, Raymond James, JMP Securities, and Cowen, an Overweight at Pacific Crest, a Buy at Goldman Sachs, and a Neutral at JPMorgan. 5. Synacor (SYNC) initiated with a Buy on upcoming growth at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/17
JPMS
04/18/17
INITIATION
Target $29
JPMS
Neutral
Arconic initiated with a Neutral at JPMorgan
JPMorgan analyst Seth Seifman started Arconic with a Neutral rating and $29 price target. The analyst views Klaus Kleinfeld's resignation as a plus and sees "significant" earnings growth ahead, but notes the stock is already up 44% year-to-date.
CENX Century Aluminum
$14.35

-0.79 (-5.22%)

02/28/17
DBAB
02/28/17
DOWNGRADE
Target $10
DBAB
Sell
Century Aluminum downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Jorge Beristain downgraded Century Aluminum (CENX) to Sell citing valuation following the recent rally in the shares. To reflect his firm's increased aluminum forecasts, the analyst upped his price target for Century to $10 from $9 and Hold-rated Alcoa (AA) to $37 from $32.50.
01/19/17
STPT
01/19/17
DOWNGRADE
STPT
Hold
Century Aluminum downgraded to Hold from Buy at Standpoint Research
10/28/16
JPMS
10/28/16
UPGRADE
Target $7
JPMS
Neutral
Century Aluminum upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Michael Gambardella upgraded Century Aluminum to Neutral citing his firm's higher LME aluminum price forecasts. The global aluminum market appears more balanced in the near term, Gambardella tells investors in a research note. He has a $7 price target for the shares.
03/27/17
MSCO
03/27/17
NO CHANGE
MSCO
Steel cost deflatoin could lead to a near-term price peak, says Morgan Stanley
Morgan Stanley analyst Evan Kurtz said East Coast export scrap prices have fallen $30/ton, which could negatively influence April scrap price settlements. The analyst said with no clear change in supply-demand dynamics, coast deflation could lead to a near-term price peak. Kurtz would view any weakness in the space as an opportunity to buy top picks Nucor (NUE), Steel Dynamics (STLD), and U.S. Steel (X).
MRK Merck
$62.97

-0.22 (-0.35%)

06/05/17
PIPR
06/05/17
NO CHANGE
PIPR
Piper views AstraZeneca, J&J as ASCO standouts
The standouts at ASCO over the weekend were the "compelling results" presented on Johnson & Johnson's (JNJ) Zytiga from the Latitude study in prostate cancer and AstraZeneca's (AZN) Lynparza in the OlympiAD trial in BRCA mutant breast cancer, Piper Jaffray analyst Richard Purkiss tells investors in a research note. In lung cancer, Merck's (MRK) updated data in KN021G "appears more promising" than Bristol-Myers' (BMY) updated data in CM012, the analyst adds. Purkiss believes, however, that relative to recent ASCOs, the data "so far in totality is underwhelming."
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/06/17
BMOC
06/06/17
NO CHANGE
BMOC
Incyte should be bought on recent weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that data on the combination of Bristol-Myers' (BMY) Opdivo and Incyte's (INCY) epacadostat "confirmed the benefit" seen in a previous study. The analyst says that the safety of Merck's (MRK) Keytruda in combination with epacadostat is better than the standard of care. He keeps a $166 price target and Outperform rating on Incyte.
06/13/17
FBCO
06/13/17
NO CHANGE
FBCO
Outperform
Merck Keytruda trials pause doesn't seem like major concern, says Credit Suisse
After speaking with Merck, Credit Suisse analyst Vamil Divan said the company confirmed that its pause of two trials of Keytruda in multiple myeloma is not a clinical hold. While it is still difficult to draw meaningful conclusions, Divan doesn't believe this is a major concern given Keytruda's clean safety profile to date. The analyst, who adds that he doesn't see any material impact on Merck's near-term prospects in immuno-oncology from this pause, keeps an Outperform rating on the stock.
SNY Sanofi
$47.73

-0.04 (-0.08%)

05/11/17
BREN
05/11/17
DOWNGRADE
BREN
Hold
Sanofi downgraded to Hold from Buy at Berenberg
Berenberg analyst Alister Campbell downgraded Sanofi to Hold citing valuation.
06/12/17
LEER
06/12/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron's Dupixent tracking well above consensus, says Leerink
Leerink analyst Geoffrey Porges says prescription trends suggest Regeneron (REGN) and Sanofi's (SNY) Dupixent will "comfortably exceed" current sell-side consensus expectations for this quarter and year. After 10 weeks, the prescription launch trajectory "remains very robust," Porges tells investors in a research note. The analyst views his Q2 sales estimate of $31M, versus the $16M consensus, as "reasonable," and feels full year sales of $200M-300M, versus the consensus of $135-$140M, is likely. He reiterates an Outperform rating on Regeneron shares.
04/11/17
04/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Conviction Buy from Buy at Goldman with analyst Drew Borst saying that the success of "Beauty and the Beast" has increased his confidence in his forecast that FY18 EPS growth will accelerate given the company's promising film slate and its read-through to consumer products. He also sees accelerating profit growth at ESPN given normalizing NBA costs and predicts record results for the Theme Parks segment. Borst keeps a $138 price target on Disney shares. 2. McDonald's (MCD) upgraded to Buy from Neutral at Cleveland Research. 3. Yelp (YELP) upgraded to Overweight from Sector Weight at Pacific Crest with analyst Brad Erickson saying his checks with local ad customers indicate Yelp's core franchise is healthy and appears insulated from larger competitors like Google (GOOG, GOOGL) and Facebook (FB). 4. Toll Brothers (TOL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Robert Wetenhall citing "solid demand,strong execution, proven management, a strong luxury housing business, and consistent earnings." 5. Sanofi (SNY) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he no longer sees downside to consensus estimates. The pressure on the diabetes business now seems largely reflected in estimates, Vosser tells investors in a research note. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JNJ Johnson & Johnson
$134.35

1.31 (0.98%)

06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
BMY Bristol-Myers
$54.46

0.18 (0.33%)

06/06/17
RHCO
06/06/17
NO CHANGE
RHCO
Bristol-Myers data 'encouraging,' says SunTrust
SunTrust analyst John Boris says that the data on a combination utilizing Bristol-Myers' Opdivo in colorectal cancer was "encouraging," although only a small number of patients participated in the trial. He says that FDA action involving Opdivo's use as a treatment for colorectal cancer and hepatic cancer can be catalysts for the stock. However, he keeps a Hold rating on Bristol-Myers.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Credit Suisse sees no impact to Incyte's epacadostat from NewLink IDO news
Credit Suisse analyst Alethia Young said she is not surprised that Roche (RHHBY) returned IDO inhibitor GDC-0919 to NewLink (NLNK) after seeing the "disappointing data" at ASCO. She doesn't see an impact to Incyte's (INCY) own IDO inhibitor, epacadostat, from the news, as she thought the data made GDC-0919 appear clinically inferior to epacadostat in combination with PD-1. She keeps an Outperform rating on Incyte shares, adding that investors may get another update on Bristol-Myers' (BMY) internal IDO, BMS-986205, later this year.
PFE Pfizer
$32.97

0.16 (0.49%)

05/16/17
05/16/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Sell from Neutral at Citi with analyst Andrew Baum saying his concern over Pfizer's "rising risk to high price" Medicare Part D covered oncology drugs, namely Xtandi, Ibrance and Xalkori, has intensified. He also believes "major transaction risk" for Pfizer remains high. 2. MercadoLibre (MELI) downgraded to Neutral from Overweight at JPMorgan with analyst Andre Baggio citing valuation with the stock up 131% year-over-year. 3. Eli Lilly (LLY) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jami Rubin citing strong year-to-date performance. The analyst maintained a Buy rating and $92 price target citing favorable long-term fundamentals with significant margin expansion. 4. Valero (VLO) downgraded to Neutral from Buy at Goldman Sachs with analyst Neil Mehta citing a more balanced risk/reward following the stock's outperformance. 5. NantKwest (NK) downgraded to Sell from Neutral at Citi with analyst Joel Beatty saying the company has a history of "significantly missing" its clinical trial timelines, and this is unlikely to change over the near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/25/17
PIPR
05/25/17
NO CHANGE
PIPR
Piper calls AbbVie and Pfizer dividends 'compelling'
In a research note on large-cap Pharma, Piper Jaffray analyst Richard Purkiss calls the dividends of AbbVie (ABBV) and Pfizer (PFE) "compelling." These two dividends "stand out with an unusually compelling combination of high yield alongside a high growth outlook," Purkiss tells investors in a research note, citing his analysis. He reiterates Overweight ratings on both stocks.
NVS Novartis
$80.83

0.38 (0.47%)

06/01/17
NEED
06/01/17
NO CHANGE
Target $4.5
NEED
Buy
Cryoport price target raised to $4.50 from $3.50 at Needham
Needham analyst Sean Hannan noted that Novartis (NVS) and Kite Pharma (KITE) both have Biologics License Applications nearing approval for studies believed to be supported by Cryoport (CYRX). Citing his growing comfort on clients' progress toward commercialization, he raised his price target on Cryoport to $4.50 from $3.50 and keeps a Buy rating on the "arms provider" to companies working on emerging regenerative therapies.
06/08/17
06/08/17
UPGRADE
Target $100

Buy
Kite Pharma upgraded to Buy on Axi-Cel manufacturing edge at BTIG
As previously reported, BTIG analyst Dane Leone upgraded Kite Pharma (KITE) to Buy from Neutral and set a $100 price target on the shares. Data from Novartis (NVS) and Juno (JUNO) have failed to deliver any recognizable differentiation, though Leone gives Kite "a clear win" for the manufacturing of Axi-Cel versus peers, he tells investors. The analyst sees Kite having the cleanest pathway to approval for diffuse large B-cell lymphoma and, given Kite's manufacturing edge, he estimates that Axi-Cel can take about 60% of share within the U.S. DLBCL market.
06/06/17
LEER
06/06/17
NO CHANGE
Target $100
LEER
Outperform
bluebird data among most impressive in CAR-T space, says Leerink
Leerink analyst Michael Schmidt says bluebird bio's (BLUE) bb2121 dose-escalation data in multiple myeloma is among the most impressive early data sets he's seen in the CAR-T space to date. The data sets a high bar for the competition, which includes Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS), Schmidt tells investors in a research note. Being one year ahead of the competition provides bluebird and Celgene (CELG) with an ideal position in multiple myeloma, the analyst adds. He keeps an Outperform rating on bluebird shares with a $100 price target.
AZN AstraZeneca
$34.54

0.43 (1.26%)

06/01/17
RHCO
06/01/17
NO CHANGE
RHCO
SunTrust sees $240/share takeout price for Tesaro
After the Wall Street Journal reported yesterday that Tesaro (TSRO) is exploring a sale, albeit with "modest" interest, SunTrust analyst Peter Lawson says his analysis suggests a $240 per share takeout price for the company. Tesaro closed yesterday up $5.88, or 4%, to $149.31. Acquisitions in the PARP inhibitor space are more likely to happen after Clovis Oncology's (CLVS) ARIEL 3 data at the end of June, as the readout will provide a more apples-to-apples comparison to Tesaro and AstraZeneca (AZN), Lawson tells investors in a research note. His "bull case" points to a $286 per share price for Tesaro and $92 per share price for Clovis. Lawson has Buy ratings on both names. JPMorgan's Cory Kasimov this morning said he likes the setup for Clovis shares into the late June data announcement.
05/17/17
JPMS
05/17/17
UPGRADE
Target $72
JPMS
Overweight
Clovis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib.
GSK GlaxoSmithKline
$43.82

0.39 (0.90%)

05/26/17
05/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. GlaxoSmithKline (GSK) upgraded to Buy from Hold at Berenberg with analyst Alistair Campbell saying Glaxo's long-term value is emerging and the market underappreciates the strength and breadth of its diversified business. 2. Rayonier Advanced Materials (RYAM) was upgraded to Buy from Hold at Vertical Research and to Buy from Neutral at BofA/Merrill. 3. Red Robin (RRGB) upgraded to Buy from Hold at Canaccord with analyst Lynne Collier citing greater confidence in its top-line drivers and in stable to improving casual dining trends. Collier raised her price target to $90 from $72 on Red Robin shares. 4. Star Bulk Carriers (SBLK) upgraded to Buy on valuation at Seaport Global with analyst Magnus Fyhr citing the pullback in shares and favorable drybulk market fundamentals. Fyhr raised his price target on Star Bulk shares to $13 from $11.50. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/30/17
JPMS
05/30/17
NO CHANGE
JPMS
Overweight
JPMorgan 'generally encouraged' by Gilead bictegravir data
After Gilead (GILD) announced top-line data from four Phase 3 studies of its HIV combo regimen containing bictegravir, JPMorgan analyst Cory Kasimov said he was "generally encouraged by the news, though not entirely surprised" given the previously communicated Phase 2 results. As he has previously noted, Kasimov thinks the launch of the bictegravir combo in 2018 could be key for Gilead to help maintain market share in the face of continued growth of GlaxoSmithKline's (GSK) dolutegravir combo and a wave of patent expirations. The analyst keeps an Overweight rating on Gilead shares.
05/30/17
LEER
05/30/17
NO CHANGE
Target $74
LEER
Market Perform
Gilead HIV combo data should reassure investors, says Leerink
Leerink analyst Geoffrey Porges said Gilead's (GILD) Phase 3 data for its HIV combination treatment featuring bictegravir should "provide significant reassurance for investors" given that the drug is an essential part of the company's HIV strategy and portfolio and was found to be equal to, though not better than, the "gold standard," namely GlaxoSmithKline's (GSK) dolutegravir combo. Porges, who attributes $12-13 per share in value from bictegravir in his current model for Gilead, notes that his peak global forecast of $10.6B for bictegravir containing combination revenue is nearly double the current consensus peak sales estimate of $5.6B. Porges keeps a Market Preform rating and $74 price target on Gilead shares.
LLY Eli Lilly
$81.88

-0.17 (-0.21%)

06/12/17
LEER
06/12/17
NO CHANGE
Target $90
LEER
Outperform
Eli Lilly price target lowered to $90 from $93 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Eli Lilly (LLY) to $90 to reflect reduced sales forecasts for baricitinib, an oral JAK1/2 inhibitor to treat rheumatoid arthritis which the company collaborates with Incyte (INCY). Following AbbVie's (ABBV) positive Phase 3 data last week for its JAK1 inhibitor upadacitinib, Fernandez dropped his U.S. peak sales estimate for baricitinib by more than 50% to $400M and pushed out his U.S. launch time to 2020 from 2018. The analyst keeps an Outperform rating on Lilly shares.
FDX FedEx
$210.50

0.05 (0.02%)

06/06/17
GHSC
06/06/17
INITIATION
GHSC
Neutral
FedEx initiated with a Neutral at Seaport Global
Seaport Global analyst Kevin Sterling initiated FedEx with a Neutral saying a lot of good news is already reflected in valuation and with Amazon potentially developing its own integrated network, shares could be under pressure near-term.
06/12/17
STFL
06/12/17
NO CHANGE
STFL
FedEx shares likely to advance to $225, says Stifel
After attending a conference, Stifel analyst David Ross says that air freight trends remain "healthy," and he expects that trend to continue through the end of the year, Ross quotes the firm's.technical analyst as saying that the stock is "near a breakout," and he thinks that the shares are likely to rise to $225 before going back to $190. Ross keeps a Hold rating on the shares.
06/15/17
OPCO
06/15/17
NO CHANGE
Target $229
OPCO
Outperform
FedEx price target raised to $229 from $218 at Oppenheimer
Oppenheimer analyst Scott Schneeberger raised his price target for FedEx to $229 on expectations for "strong" earnings growth in FY18. The analyst expects a "solid" finish to FY17 and thinks next fiscal year will provide a "favorable initial indication" of the combined FedEx Express/TNT Express entity. He reiterates an Outperform rating on the shares.
06/06/17
06/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hartford Financial (HIG) initiated with a Buy at Deutsche Bank. 2. FedEx (FDX) and UPS (UPS) were initiated with a Neutral at Seaport Global. 3. Gardner Denver (GDI) was initiated with an Outperform at William Blair and Baird, an Overweight at Piper Jaffray, a Buy at Stifel, UBS, and Goldman Sachs, as well as a Neutral at Credit Suisse. 4. Solaris Oilfield (SOI) was initiated with an Outperform at Wells Fargo, Oppenheimer, Evercore ISI, and Credit Suisse, an Overweight at Piper Jaffray, as well as a Buy at Goldman Sachs and Wunderlich. 5. LeMaitre (LMAT) initiated with a Hold at Craig-Hallum. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
APEI American Public Education
$23.90

0.35 (1.49%)

11/10/16
PIPR
11/10/16
NO CHANGE
PIPR
Piper sees regulatory pressure on education industry easing
Piper Jaffray analyst Peter Appert thinks regulatory pressure in the education industry could "ease meaningfully" in the Trump administration. The sector could see a "positive reset in valuations" after significant underperformance over the last several years, Appert tells investors in a research note. His top picks in the space are DeVry (DV) and Grand Canyon (LOPE).
BPI Bridgepoint Education
$14.12

0.06 (0.43%)

01/17/17
BRRR
01/17/17
NO CHANGE
Target $14
BRRR
Outperform
Bridgepoint Education price target raised to $14 from $9 at Barrington
Barrington analyst Alexander Paris raised his price target on Bridgepoint Education shares to $14 from $9 as he believes a higher multiple is appropriate for the stock, and the for-profit education group, given the less hostile regulatory environment likely under incoming President Trump and his administration.
03/10/17
BRRR
03/10/17
NO CHANGE
Target $14
BRRR
Outperform
Bridgepoint share buyback reflects management confidence, says Barrington
After Bridgepoint Education agreed to buy back about 18M shares from private equity investor Warburg Pincus for $150M Barrington analyst Alexander Paris said "the only surprise" from his perspective is that the deal came sooner than expected. Also, he believes the deal suggest company management and the board are comfortable with regulatory risk and the direction of the business. Paris keeps an Outperform rating and $14 price target on Bridgepoint shares.
CECO Career Education

ATGE Adtalem Global Education
$37.10

-0.2 (-0.54%)

05/26/17
PIPR
05/26/17
NO CHANGE
Target $52
PIPR
Overweight
Adtalem Global Education price target raised to $52 from $46 at Piper Jaffray
Piper Jaffray analyst Peter Appert raised his price target for Adtalem Global Education to $52 following the company's investor day. The analyst sees improving enrollment trends in the medical unit, positive margin momentum and earnings leverage from buybacks as near-term catalysts for the stock. He keeps an Overweight rating on the name.
LOPE Grand Canyon
$81.33

0.74 (0.92%)

05/05/17
PIPR
05/05/17
NO CHANGE
Target $81
PIPR
Overweight
Grand Canyon price target raised to $81 from $73 at Piper Jaffray
Piper Jaffray analyst Peter Appert raised his price target for Grand Canyon Education to $81 following the company's beat and raise quarter. Grand Canyon remains the industry leader in enrollments, revenue and earnings growth, Appert tells investors in a post-earnings research note. He keeps an Overweight rating on the shares.
05/05/17
BARD
05/05/17
NO CHANGE
Target $84
BARD
Outperform
Grand Canyon price target raised to $84 from $71 at Baird
Baird analyst Jeffrey Meuler raised his price target on Grand Canyon to $84 from $71 following Q3 results that showed new enrollment growth, strong GCU performance, and what appears to be conservative operating estimates. Meuler reiterated his Outperform rating on Grand Canyon shares.
03/13/17
FBCO
03/13/17
NO CHANGE
Target $75
FBCO
Outperform
Grand Canyon price target raised to $75 from $64 at Credit Suisse
Credit Suisse analyst Trace Urdan raised his price target for Grand Canyon to $75 from $64 based on modest enrollment and revenue growth, conservative cost case and beta well above recent history. The analyst reiterates an Outperform rating on the shares.
03/20/17
PIPR
03/20/17
NO CHANGE
Target $73
PIPR
Overweight
Grand Canyon a 'compelling investment opportunity,' says Piper Jaffray
Piper Jaffray analyst Peter Appert calls Grand Canyon Education a "compelling investment opportunity" and upped his price target for the shares to $73 from $69. Grand Canyon's industry-leading enrollment, revenue and earnings growth is likely to continue, Appert tells investors in a research note. The analyst keeps an Overweight rating on the shares.
ESI ITT Educational

08/26/16
PIPR
08/26/16
DOWNGRADE
PIPR
Underweight
ITT Educational downgraded to Underweight after enrollment ban at Piper Jaffray
Piper Jaffray analyst Peter Appert said the Department of Education's new ban on ITT Education enrolling new students will likely be the "final blow" and he assumes the company will face bankruptcy and/or shutdown over next 12 months. Appert cut his price target on ITT shares to $0 from $3.
08/26/16
BRRR
08/26/16
DOWNGRADE
BRRR
Underperform
ITT Educational downgraded to Underperform from Market Perform at Barrington
Barrington analyst Alexander Paris downgraded ITT Educational to Underperform from Market Perform, saying that the DOE's actions will effectively force the company into bankruptcy.
08/26/16
08/26/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. B. Riley downgraded Nike (NKE) to Neutral and maintained its $62 price target, with analyst Mitch Kummetz saying Nike basketball has improved sequentially, but is more than offset by running weakness. He expects futures to be flat to down sequentially when Nike reports next month. 2. Telsey Advisory downgraded Viacom (VIAB) to Market Perform from Outperform, as analyst Tom Egan believes a Viacom credit downgrade is a real threat following Moody's lowered its rating outlook to negative from stable last month. Egan said Viacom's fundamentals continue to trail every other major U.S. entertainment company and said a turn-around in FY17 is unlikely. 3. CLSA analyst Man Ho Lam downgraded SouFun (SFUN) to Sell, as he believes secondary brokerage momentum has stalled with GMV and volume down sequentially, and could continue into 2H 2016. 4. Citi analyst Paul Lejuez downgraded Signet Jewelers (SIG) to Neutral from Buy, citing its weakening fundamentals. Zale's weakness in the past two quarters makes him question if that business is likely to close the sales productivity and profit gap versus Kay, as he'd previously assumed was possible, said Lejuez, who cut his price target on Signet shares to $83 from $125. 5. Piper Jaffray analyst Peter Appert downgraded ITT Educational (ESI) to Underweight, stating that the Department of Education's new ban on ITT Education enrolling new students will likely be the "final blow." He assumes the company will face bankruptcy and/or shutdown over next 12 months and cut his price target on ITT shares to $0 from $3. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
STRA Strayer
$93.17

0.08 (0.09%)

TODAY'S FREE FLY STORIES

KMX

CarMax

$68.84

0.17 (0.25%)

, FINL

Finish Line

$9.22

-0.21 (-2.23%)

20:25
09/21/17
09/21
20:25
09/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KMX

CarMax

$68.84

0.17 (0.25%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:47
09/21/17
09/21
18:47
09/21/17
18:47
Periodicals
HP Enterprise planning approximately 5,000 job cuts, Bloomberg reports »

In part of a broader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

RP

RealPage

$39.35

-0.1 (-0.25%)

18:41
09/21/17
09/21
18:41
09/21/17
18:41
Hot Stocks
RealPage expects $3M-$4M of renter's insurance claims from hurricanes »

RealPage announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:39
09/21/17
09/21
18:39
09/21/17
18:39
Periodicals
Breaking Periodicals news story on HP Enterprise »

HP Enterprise planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

YUM

Yum! Brands

$76.48

0.11 (0.14%)

18:37
09/21/17
09/21
18:37
09/21/17
18:37
Conference/Events
Yum! Brands management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MAR

Marriott

$107.57

-0.12 (-0.11%)

18:32
09/21/17
09/21
18:32
09/21/17
18:32
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ESPGY

Esprit Holdings

$1.21

0.018 (1.51%)

18:29
09/21/17
09/21
18:29
09/21/17
18:29
Conference/Events
Esprit Holdings management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BA

Boeing

$256.04

0.58 (0.23%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Hot Stocks
Boeing: Turkish Airlines announces intent to order 40 787-9 Dreamliners »

Boeing and Turkish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

M

Macy's

$21.16

-0.32 (-1.49%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Conference/Events
Macy's management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

TAHO

Tahoe Resources

$5.60

0.02 (0.36%)

18:12
09/21/17
09/21
18:12
09/21/17
18:12
Hot Stocks
Tahoe Resources raises 2017 gold operations view to 400K-500K »

Tahoe Resources updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$18.42

0.02 (0.11%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Conference/Events
Atkore management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

, TXN

Texas Instruments

$86.05

0.22 (0.26%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

TXN

Texas Instruments

$86.05

0.22 (0.26%)

PSDO

Presidio

$13.95

-0.06 (-0.43%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 21

    Sep

FTR

Frontier Communications

$11.69

-0.31 (-2.58%)

18:10
09/21/17
09/21
18:10
09/21/17
18:10
Hot Stocks
Frontier Communications operations in Florida return to near-normal levels »

Daily operations for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$10.66

-0.06 (-0.56%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Playa Hotels & Resorts reports no significant damage from Maria »

Playa Hotels &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Ascendis spikes higher after Versartis Velocity trial fails to meet endpoint »

Shares of Ascendis Pharma…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$103.90

-0.04 (-0.04%)

18:04
09/21/17
09/21
18:04
09/21/17
18:04
Hot Stocks
Celanese increases price of acetyl intermediates »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNOW

NOW Inc.

$12.98

0.1 (0.78%)

18:03
09/21/17
09/21
18:03
09/21/17
18:03
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

JOBS

51job

$58.50

0.01 (0.02%)

18:02
09/21/17
09/21
18:02
09/21/17
18:02
Hot Stocks
51job announces strategic investment in Lagou »

51job announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$43.63

0.17 (0.39%)

17:53
09/21/17
09/21
17:53
09/21/17
17:53
Conference/Events
Hess Corp. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

APC

Anadarko

$48.49

3.68 (8.21%)

17:43
09/21/17
09/21
17:43
09/21/17
17:43
Recommendations
Anadarko analyst commentary at MUFG »

Anadarko buyback a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

HCC

Warrior Met Coal

$23.28

-1.05 (-4.32%)

17:42
09/21/17
09/21
17:42
09/21/17
17:42
Hot Stocks
Warrior Met Coal receives favorable IRS private letter ruling »

Warrior Met Coal reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAA

MAA

$107.27

-0.03 (-0.03%)

17:35
09/21/17
09/21
17:35
09/21/17
17:35
Hot Stocks
MAA announces estimated impact of Hurricanes Irma and Harvey »

MAA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$280.42

0.38 (0.14%)

17:31
09/21/17
09/21
17:31
09/21/17
17:31
Hot Stocks
Northrop Grumman awarded $124.7M government contract »

Northrop Grumman Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$205.72

1.45 (0.71%)

17:29
09/21/17
09/21
17:29
09/21/17
17:29
Hot Stocks
General Dynamics Electric Boat awarded $5B government contract »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAN

Aaron's

$38.83

-0.39 (-0.99%)

17:19
09/21/17
09/21
17:19
09/21/17
17:19
Hot Stocks
Aaron's provides update on impact of Hurricane Irma »

Aaron's plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.